FINWIRES · TerminalLIVE
FINWIRES

研究快讯:华纳兄弟探索频道(Warner Bros. Discovery, Inc.)公布2026年第一季度业绩喜忧参半

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:华纳兄弟影业(WBD)公布了2026年第一季度业绩,表现喜忧参半。营收同比下降1%至80亿美元,净亏损29亿美元,而上年同期则盈利4.53亿美元。亏损的主要原因是派拉蒙影业旗下天空之舞影业(Paramount Skydance)即将完成收购,导致Netflix支付了28亿美元的终止费。剔除一次性费用后,尽管NBA赛事停播导致广告收入下降7%,但调整后EBITDA仍保持稳健,达到22亿美元(不计汇率影响)。我们认为,其核心业务展现出令人鼓舞的流媒体增长势头,该业务板块营收(不计汇率影响)增长7%至29亿美元,调整后EBITDA增长29%,主要得益于HBO Max在英国、爱尔兰、德国和意大利等国际市场的成功上线。派拉蒙影业收购天空之舞传媒的交易预计将于2026年第三季度完成。我们预计流媒体用户持续增长将抵消传统电视网络用户下滑的影响,但由于内容投资增加和交易成本上升,自由现金流由之前的3.02亿美元转为负值,为-4.76亿美元。公司目前净杠杆率为3.4倍,现金储备达33亿美元,在完成此次收购的过程中保持着财务灵活性。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661